<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041483</url>
  </required_header>
  <id_info>
    <org_study_id>C-01-99</org_study_id>
    <nct_id>NCT00041483</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD</brief_title>
  <official_title>Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that Anecortave Acetate is as effective after
      twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible
      for initial PDT treatment for wet age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Maintaining Vision</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Anecortave and Sham PDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDT and Sham Anecortave Acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate 15 mg sterile suspension</intervention_name>
    <arm_group_label>Anecortave and Sham PDT</arm_group_label>
    <arm_group_label>PDT and Sham Anecortave Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Photodynamic Therapy (PDT)</intervention_name>
    <arm_group_label>Anecortave and Sham PDT</arm_group_label>
    <arm_group_label>PDT and Sham Anecortave Acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV
        due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to 20/400
        (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases will be
        excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2002</study_first_submitted>
  <study_first_submitted_qc>July 31, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2002</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>age-related macular degeneration</keyword>
  <keyword>Anecortave</keyword>
  <keyword>Acetate</keyword>
  <keyword>Wet form of age-related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anecortave</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

